Published finding — does the expert body still believe it?
Compared to enalapril, LCZ696 is associated with higher rates of hypotension and non-serious angioedema but lower rates of renal impairment, hyperkalemia, and cough in HFrEF patients.
TL;DR · AI-generated
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.
Author-implied confidence
88%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
95% → 95% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
· openalex W2113698123 · s2 9ca73cac
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1166
LCZ696 reduces the risk of hospitalization for heart failure by 21% compared to enalapril in patients with NYHA class II–IV HFrEF.
0.1198
LCZ696 reduces cardiovascular mortality by 20% compared to enalapril in HFrEF patients, with a hazard ratio of 0.80 (95% CI 0.71–0.89).
0.1333
LCZ696 (sacubitril/valsartan) 200 mg twice daily reduces the composite of cardiovascular death or heart failure hospitalization by 20% compared to enalapril 10 mg twice daily in patients with HFrEF (EF ≤40%), with a hazard ratio of 0.80 (95% CI 0.73–0.87).
0.1345
LCZ696 reduces all-cause mortality by 16% compared to enalapril in patients with NYHA class II–IV heart failure and reduced ejection fraction, with a hazard ratio of 0.84 (95% CI 0.76–0.93).
0.1543
LCZ696 will demonstrate superiority over enalapril in reducing cardiovascular death or heart failure hospitalization across diverse real-world HFrEF populations, including those underrepresented in PARADIGM-HF.
0.1864
The PARADIGM-HF trial's stated primary conclusion — Sacubitril/valsartan (ARNI) reduces CV death and HF hospitalization vs. enalapril in HFrEF. — replicates in independent cohorts.